CBP/β-Catenin/FOXM1 Is a Novel Therapeutic Target in Triple Negative Breast Cancer

Background: Triple negative breast cancers (TNBCs) are an aggressive BC subtype, characterized by high rates of drug resistance and a high proportion of cancer stem cells (CSC). CSCs are thought to be responsible for tumor initiation and drug resistance. cAMP-response element-binding (CREB) binding...

Descripción completa

Detalles Bibliográficos
Autores principales: Ring, Alexander, Nguyen, Cu, Smbatyan, Goar, Tripathy, Debu, Yu, Min, Press, Michael, Kahn, Michael, Lang, Julie E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315782/
https://www.ncbi.nlm.nih.gov/pubmed/30572639
http://dx.doi.org/10.3390/cancers10120525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315782/
https://www.ncbi.nlm.nih.gov/pubmed/30572639
http://dx.doi.org/10.3390/cancers10120525

Ejemplares similares